
Pro-Dex (PDEX) Stock Forecast & Price Target
Pro-Dex (PDEX) Analyst Ratings
Bulls say
Pro-Dex Inc has demonstrated a positive financial trajectory, highlighted by a year-over-year revenue increase of 22%, attributed to the growth in new medical device product sales and repairs. The company's gross margins have also improved, reaching 33% year-over-year, indicating enhanced operational efficiency and profitability. Furthermore, the management's successful acquisition of new product contracts and investment in private label offerings are expected to continue fostering substantial growth in the future.
Bears say
Pro-Dex Inc. has recently adjusted its fiscal year 2025 revenue estimates to $67 million, a decrease from the previous estimate of $68 million, and revised its earnings per share (EPS) forecast downward to $2.81 from $2.30. This adjustment reflects potential challenges in meeting revenue goals amid a competitive landscape and evolving demand for technology in the medical device sector. Furthermore, risks stemming from macroeconomic factors, shifts in consumer sentiment, and the overall investor outlook for technology stocks may further hinder the company's financial performance and stock prospects.
This aggregate rating is based on analysts' research of Pro-Dex and is not a guaranteed prediction by Public.com or investment advice.
Pro-Dex (PDEX) Analyst Forecast & Price Prediction
Start investing in Pro-Dex (PDEX)
Order type
Buy in
Order amount
Est. shares
0 shares